SKAN provides in-depth insight into its growth strategy and pre-approved services on its first Capital Market Day

Media Information

SKAN provides in-depth insight into its growth strategy and pre-approved services on its first Capital Market Day

Today marks the SKAN Group's first Capital Market Day in Allschwil. Investors, analysts, and representatives of the financial media will be informed about the structural growth drivers of the isolator market, the industry environment, and SKAN's strategy. They will also gain in-depth insight into isolator technology, planned new services, and investment projects. Other topics include managing strong growth, strengthening the unique corporate culture, and the importance of regulatory requirements. A highlight will be a tour of the new facility for Pre-Approved Services. The mid-term targets will be confirmed.

Allschwil, 15 May 2025 – The SKAN Group is focused on a market that is benefiting from structural growth. Growth drivers include demographic trends and the increase in chronic diseases, advances in biotechnology, and new medical applications. The trend toward injectable drugs will continue, as will the shift from traditional cleanrooms to superior isolator technology. Accordingly, customer demand for process solutions for aseptic filling and for the associated services and consumables will continue to grow. As the clear market leader in a market with a relatively stable supplier structure, SKAN benefits from clear competitive advantages: its reputation as a quality supplier, its technological edge, its process expertise, and its extensive service network.

SKAN continues to drive growth and strengthens its market leadership

The SKAN Group is pursuing a clear strategy to ensure that it continues to benefit above average from future market developments. The cornerstones of this strategy are, firstly, to fortify the market leadership in core markets through investment in key competencies and the expansion of production capacities. Continued high levels of innovation will consolidate the technological leadership, while increasing the degree of standardization in both assemblies and processes will enable efficiency gains and shorten development and delivery times. Dialogue with regulators, including their training, provides SKAN with in-depth knowledge of regulatory requirements and enables it to provide appropriate support to its customers.

The second cornerstone is to expand the addressable market towards integrated process systems and to increase the share of wallet among existing customers. The company's own robotics initiative for AT-Closed Vial^® and established partnerships with filling line manufacturers play an important role here. Thirdly, sales of aftermarket services and consumables are to be increased, including Pre-Approved Services as a significant initiative. Finally, the fourth pillar is the acceleration of the digital transformation.

The unique SKAN culture remains a key factor in the company's success. To keep pace with dynamic workforce growth, SKAN is implementing measures to preserve its corporate culture and secure its expertise. This includes actively promoting the integration of new employees without diluting the company's cultural strengths.

Mid-term targets confirmed

With the successful implementation of its strategy, the SKAN Group will continue to secure its profitable growth in the future and achieve the anticipated margin expansion. Against this backdrop, the Group confirmed its medium-term targets at its Capital Markets Day: It expects net sales to grow at an annual rate in the mid- to upper teens, with the Services & Consumables segment growing faster than Equipment & Solutions. The EBITDA margin is to be gradually increases to the upper teens in the mid-term, with potential for further increase beyond mid-term period.

The implementation of the strategy and the planned organic growth investments will be financed from cash generated by the company.

Competitive advantages for customers through Pre-Approved Services

A highlight of the Capital Markets Day will be a tour of the new facility for Pre-Approved Services. SKAN will offer customers the opportunity to carry out the stability tests required for drug approval at an early stage, while their filling line is being constructed in parallel. This will enable customers to significantly reduce the time to market for a new drug, giving them a significant competitive advantage.

The facility is currently undergoing qualification. Inspection by the Swiss regulatory authority is scheduled for the first quarter of 2026, with commercial operations expected to commence in the second half of 2026.

Webcast (in English):

15 May 2025
9.00 am until approx. 12.45 pm

The Capital Markets Day presentations will be broadcast as a live webcast. To access the webcast, please use this link.

Download Link:

>> Presentation Capital Markts Day 2025

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs approximately 1500 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan, the USA and Brazil.